Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors
Conditions
Interventions
TAS-119
Locations
6
United States
University Hospitals - Seidman Cancer Center
Cleveland, Ohio, United States
San Raffaele Hospital
Milan, Italy
Erasmus MC Cancer Institute
Rotterdam, Netherlands
START MADRID-FJD, Hospital Fundación Jiménez Díaz
Madrid, Spain
START Madrid Unidad de Ensayos Fase I
Madrid, Spain
The Institute of Cancer Research
Sutton, Surrey, United Kingdom
Start Date
September 1, 2014
Primary Completion Date
August 1, 2019
Completion Date
August 1, 2019
Last Updated
September 4, 2024
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Taiho Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions